{
    "clinical_study": {
        "@rank": "41784", 
        "acronym": "702", 
        "arm_group": {
            "arm_group_label": "EXPAREL", 
            "arm_group_type": "Experimental", 
            "description": "undiluted EXPAREL 266 mg"
        }, 
        "brief_summary": {
            "textblock": "Phase 4 study evaluating the effectiveness of EXPAREL when infiltrated into the  the\n      Transversus Abdominis Plane (TAP)."
        }, 
        "brief_title": "EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "undiluted EXPAREL 266 mg", 
                        "title": "EXPAREL"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "13"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "13"
                                            }
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "12.72", 
                                            "@value": "45.7"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "3"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "10"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "13"
                                        }
                                    }, 
                                    "sub_title": "United States"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "The effectiveness of abdominal analgesia from the infiltration into the TAP as measured by the subject's overall postsurgical analgesic use in morphine equivalents (mg)", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects receiving 266 mg EXPAREL to infiltrate into the bilateral TAPs.", 
                                "title": "EXPAREL"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@spread": "17.41", 
                                                    "@value": "9.7"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "The effectiveness of abdominal analgesia from the infiltration into the TAP as measured by the subject's overall postsurgical analgesic use in morphine equivalents (mg)", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "The Effectiveness of Abdominal Analgesia From the Infiltration Into the TAP as Measured by the Subject's Overall Postsurgical Analgesic Use", 
                                    "units": "mg (morphine equivalents)"
                                }
                            ]
                        }, 
                        "population": "The analysis population comprised all enrolled subjects.", 
                        "safety_issue": "No", 
                        "time_frame": "10 days", 
                        "title": "The Effectiveness of Abdominal Analgesia From the Infiltration Into the TAP as Measured by the Subject's Overall Postsurgical Analgesic Use", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Adverse events and serious adverse events through Day 30 will be examined in order to assess the safety of EXPAREL.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "Subjects receiving 266 mg EXPAREL to infiltrate into the bilateral TAPs.", 
                                "title": "EXPAREL"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "13"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "0"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Adverse events and serious adverse events through Day 30 will be examined in order to assess the safety of EXPAREL.", 
                                    "param": "Number", 
                                    "title": "The Safety of EXPAREL Will be Assessed by the Occurrence of All Postsurgical AEs and SAEs Through Day 30.", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "The analysis population comprised all enrolled subjects.", 
                        "safety_issue": "Yes", 
                        "time_frame": "30 days", 
                        "title": "The Safety of EXPAREL Will be Assessed by the Occurrence of All Postsurgical AEs and SAEs Through Day 30.", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "undiluted EXPAREL 266 mg", 
                        "title": "EXPAREL"
                    }
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "13", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "13", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "0", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "Subjects were not excluded.", 
                "recruitment_details": "Recruitment occurred between 20 July 2012 and 27 November 2012."
            }, 
            "point_of_contact": {
                "name_or_title": "Mark Kronefeld, MD", 
                "organization": "Maimonides Medical Center", 
                "phone": "(718) 283-8816"
            }
        }, 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hernia", 
        "condition_browse": {
            "mesh_term": [
                "Hernia", 
                "Hernia, Abdominal"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, open-label, non-randomized study evaluating the effectiveness of\n      abdominal analgesia when using 266 mg EXPAREL to infiltrate into the TAP unilaterally."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females, aged 18-75 years inclusive, and ASA physical status 1-3.\n\n          -  Undergoing open repair of a unilateral abdominal hernia below the level of the\n             umbilicus.\n\n          -  Abdominal incision length of 3-12 cm.\n\n          -  Subjects must be physically and mentally able to participate in the study and\n             complete all study assessments.\n\n          -  Subjects must be able to give fully informed consent to participate in this study\n             after demonstrating a good understanding of the risks and benefits of the proposed\n             components of the TAP infiltration.\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity or idiosyncratic reactions to amide-type local\n             anesthetics\n\n          -  Any subject whose anatomy, or surgical procedure, in the opinion of the Investigator,\n             might preclude the potential successful performance of a TAP infiltration.\n\n          -  Any subject who in the opinion of the Investigator, might be harmed or be a poor\n             candidate for participation in the study.\n\n          -  Any subject, who in the opinion of the Investigator, is on chronic pain medicine.\n\n          -  Any female subject who is currently pregnant.\n\n          -  Subjects who have received any investigational drug within 30 days prior to study\n             drug administration, or planned administration of another investigational product or\n             procedure during their participation in this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 26, 2013", 
        "firstreceived_results_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801124", 
            "org_study_id": "MA402S23B702"
        }, 
        "intervention": {
            "arm_group_label": "EXPAREL", 
            "description": "single dose 266 mg of undiluted EXPAREL", 
            "intervention_name": "EXPAREL", 
            "intervention_type": "Drug", 
            "other_name": "bupivacaine liposome injectable suspension"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "analgesia", 
            "hernia repair"
        ], 
        "lastchanged_date": "July 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brooklyn", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11219"
                }, 
                "name": "Maimonides Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Safety and Efficacy of EXPAREL\u00ae When Infiltrated Into the Transversus Abdominis Plane (TAP) for Prolonged Postoperative Analgesia in Subjects Undergoing Unilateral Abdominal Hernia Repair", 
        "overall_official": {
            "affiliation": "Maimonides", 
            "last_name": "Mark Kronenfeld, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The effectiveness of abdominal analgesia from the infiltration into the TAP as measured by the subject's overall postsurgical analgesic use in morphine equivalents (mg)", 
            "measure": "The Effectiveness of Abdominal Analgesia From the Infiltration Into the TAP as Measured by the Subject's Overall Postsurgical Analgesic Use", 
            "safety_issue": "No", 
            "time_frame": "10 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801124"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events and serious adverse events through Day 30 will be examined in order to assess the safety of EXPAREL.", 
            "measure": "The Safety of EXPAREL Will be Assessed by the Occurrence of All Postsurgical AEs and SAEs Through Day 30.", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "source": "Pacira Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pacira Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}